Actively Recruiting

Age: 18Years - 74Years
All Genders
NCT05697159

7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Led by NHS Greater Glasgow and Clyde · Updated on 2025-01-14

20

Participants Needed

1

Research Sites

114 weeks

Total Duration

On this page

Sponsors

N

NHS Greater Glasgow and Clyde

Lead Sponsor

G

Galapagos NV

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients. The investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate. The second is related to peripheral inflammation, specifically joint synovitis, blood cytokines/chemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.

CONDITIONS

Official Title

7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Who Can Participate

Age: 18Years - 74Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to less than 75 years with moderate to severe active rheumatoid arthritis
  • Patients prescribed Filgotinib according to product guidelines
  • Right-handed individuals to reduce brain imaging variability
Not Eligible

You will not qualify if you...

  • Unable to provide written informed consent
  • Severe physical impairment such as blindness, deafness, or paraplegia
  • Pregnant or breastfeeding women
  • Severe claustrophobia preventing MRI
  • Any contraindications to MRI
  • Major neurological diseases like multiple sclerosis, stroke, or traumatic brain injury
  • Previous use of targeted synthetic DMARDs (e.g., baricitinib, tofacitinib) for rheumatoid arthritis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Neil Basu

Glasgow, United Kingdom

Actively Recruiting

Loading map...

Research Team

M

Maxine Arnott

CONTACT

N

Neil Basu, MD, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here